These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Insights into pandemic respiratory viruses: manipulation of the antiviral interferon response by SARS-CoV-2 and influenza A virus. Liu G; Gack MU Curr Opin Immunol; 2022 Oct; 78():102252. PubMed ID: 36215931 [TBL] [Abstract][Full Text] [Related]
23. Structural characterization of SARS-CoV-2 dimeric ORF9b reveals potential fold-switching trigger mechanism. Jin X; Sun X; Chai Y; Bai Y; Li Y; Hao T; Qi J; Song H; Wong CCL; Gao GF Sci China Life Sci; 2023 Jan; 66(1):152-164. PubMed ID: 36184694 [TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 infection and the antiviral innate immune response. Yang H; Lyu Y; Hou F J Mol Cell Biol; 2020 Nov; 12(12):963-967. PubMed ID: 33377937 [No Abstract] [Full Text] [Related]
25. Interferon resistance of emerging SARS-CoV-2 variants. Guo K; Barrett BS; Morrison JH; Mickens KL; Vladar EK; Hasenkrug KJ; Poeschla EM; Santiago ML Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2203760119. PubMed ID: 35867811 [TBL] [Abstract][Full Text] [Related]
26. Decoupling SARS-CoV-2 ORF6 localization and interferon antagonism. Wong HT; Cheung V; Salamango DJ J Cell Sci; 2022 Mar; 135(6):. PubMed ID: 35187564 [TBL] [Abstract][Full Text] [Related]
27. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Shin D; Mukherjee R; Grewe D; Bojkova D; Baek K; Bhattacharya A; Schulz L; Widera M; Mehdipour AR; Tascher G; Geurink PP; Wilhelm A; van der Heden van Noort GJ; Ovaa H; Müller S; Knobeloch KP; Rajalingam K; Schulman BA; Cinatl J; Hummer G; Ciesek S; Dikic I Nature; 2020 Nov; 587(7835):657-662. PubMed ID: 32726803 [TBL] [Abstract][Full Text] [Related]
28. Human Nasal and Lung Tissues Infected Alfi O; Yakirevitch A; Wald O; Wandel O; Izhar U; Oiknine-Djian E; Nevo Y; Elgavish S; Dagan E; Madgar O; Feinmesser G; Pikarsky E; Bronstein M; Vorontsov O; Jonas W; Ives J; Walter J; Zakay-Rones Z; Oberbaum M; Panet A; Wolf DG J Virol; 2021 Jun; 95(14):e0013021. PubMed ID: 33893170 [TBL] [Abstract][Full Text] [Related]
29. Mechanisms of Antiviral Immune Evasion of SARS-CoV-2. Beyer DK; Forero A J Mol Biol; 2022 Mar; 434(6):167265. PubMed ID: 34562466 [TBL] [Abstract][Full Text] [Related]
30. Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. Hatton CF; Botting RA; Dueñas ME; Haq IJ; Verdon B; Thompson BJ; Spegarova JS; Gothe F; Stephenson E; Gardner AI; Murphy S; Scott J; Garnett JP; Carrie S; Powell J; Khan CMA; Huang L; Hussain R; Coxhead J; Davey T; Simpson AJ; Haniffa M; Hambleton S; Brodlie M; Ward C; Trost M; Reynolds G; Duncan CJA Nat Commun; 2021 Dec; 12(1):7092. PubMed ID: 34876592 [TBL] [Abstract][Full Text] [Related]
32. Phosphorylation of SARS-CoV-2 Orf9b Regulates Its Targeting to Two Binding Sites in TOM70 and Recruitment of Hsp90. Brandherm L; Kobaš AM; Klöhn M; Brüggemann Y; Pfaender S; Rassow J; Kreimendahl S Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502139 [TBL] [Abstract][Full Text] [Related]
33. Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors. Quarleri J; Delpino MV Cytokine Growth Factor Rev; 2021 Apr; 58():55-65. PubMed ID: 33608189 [TBL] [Abstract][Full Text] [Related]
34. The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives. Boechat JL; Chora I; Morais A; Delgado L Pulmonology; 2021; 27(5):423-437. PubMed ID: 33867315 [TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns. Redondo N; Zaldívar-López S; Garrido JJ; Montoya M Front Immunol; 2021; 12():708264. PubMed ID: 34305949 [TBL] [Abstract][Full Text] [Related]
36. The role of SARS-CoV-2 accessory proteins in immune evasion. Zandi M; Shafaati M; Kalantar-Neyestanaki D; Pourghadamyari H; Fani M; Soltani S; Kaleji H; Abbasi S Biomed Pharmacother; 2022 Dec; 156():113889. PubMed ID: 36265309 [TBL] [Abstract][Full Text] [Related]
38. Activation and evasion of type I interferon responses by SARS-CoV-2. Lei X; Dong X; Ma R; Wang W; Xiao X; Tian Z; Wang C; Wang Y; Li L; Ren L; Guo F; Zhao Z; Zhou Z; Xiang Z; Wang J Nat Commun; 2020 Jul; 11(1):3810. PubMed ID: 32733001 [TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant. Laine L; Skön M; Väisänen E; Julkunen I; Österlund P Front Immunol; 2022; 13():1016108. PubMed ID: 36248817 [TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Miorin L; Kehrer T; Sanchez-Aparicio MT; Zhang K; Cohen P; Patel RS; Cupic A; Makio T; Mei M; Moreno E; Danziger O; White KM; Rathnasinghe R; Uccellini M; Gao S; Aydillo T; Mena I; Yin X; Martin-Sancho L; Krogan NJ; Chanda SK; Schotsaert M; Wozniak RW; Ren Y; Rosenberg BR; Fontoura BMA; García-Sastre A Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28344-28354. PubMed ID: 33097660 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]